Vincent J Picozzi

Summary

Affiliation: Virginia Mason Medical Center
Country: USA

Publications

  1. ncbi request reprint Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma
    Vincent J Picozzi
    Department of General Surgery, Virginia Mason Medical Center, Seattle, WA 98111, USA
    Am J Surg 185:476-80. 2003
  2. ncbi request reprint The Virginia Mason approach to localized pancreatic cancer
    Vincent J Picozzi
    Section of Hematology Oncology, Virginia Mason Medical Center, 1100 9th Avenue, Seattle, WA 98111, USA
    Surg Oncol Clin N Am 13:663-74, ix. 2004
  3. ncbi request reprint Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma
    V J Picozzi
    Section of Hematology Oncology, Virginia Mason Medical Center, Seattle, Washington 98111, USA
    Oncology (Williston Park) 15:1296-306; discussion 1310-1, 1314. 2001
  4. ncbi request reprint Strength of the evidence: adjuvant therapy for resected pancreatic cancer
    Vincent J Picozzi
    Section of Medical Oncology, Virginia Mason Medical Center, 1100 Ninth Ave Buck 2, Seattle, WA 98111, USA
    J Gastrointest Surg 12:657-61. 2008
  5. pmc Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031
    V J Picozzi
    Department of Medical Oncology, Virginia Mason Medical Center, Seattle, WA 98111, USA
    Ann Oncol 22:348-54. 2011
  6. doi request reprint Afferent limb syndrome and delayed GI problems after pancreaticoduodenectomy for pancreatic cancer: single-center, 14-year experience
    Rahul Pannala
    Department of Gastroenterology and Hepatology, Virginia Mason Medical Center, Seattle, Washington, USA
    Gastrointest Endosc 74:295-302. 2011
  7. doi request reprint Supportive care considerations during concurrent chemoradiotherapy for pancreatic adenocarcinoma: lessons learned from clinical experience
    Andrea Wang-Gillam
    Division of Hematology Oncology, Siteman Cancer Center, Washington University in St Louis School of Medicine, St Louis, MO Department of Radiation Oncology, Rush University Medical Center Department of Surgery, University of Chicago Medical Center, Chicago, IL Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX Cancer and Digestive Diseases Institutes, Virginia Mason Medical Center, Seattle, WA
    Am J Clin Oncol 36:637-43. 2013
  8. ncbi request reprint Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma
    Andrew D Jacobs
    Section of Hematology Oncology, Virginia Mason Medical Center, Seattle, Washington 98111, USA
    Cancer Invest 22:505-14. 2004

Collaborators

Detail Information

Publications8

  1. ncbi request reprint Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma
    Vincent J Picozzi
    Department of General Surgery, Virginia Mason Medical Center, Seattle, WA 98111, USA
    Am J Surg 185:476-80. 2003
    ..This report describes the continued observations regarding this methodology with longer follow-up and more than twice the number of patients as the original report...
  2. ncbi request reprint The Virginia Mason approach to localized pancreatic cancer
    Vincent J Picozzi
    Section of Hematology Oncology, Virginia Mason Medical Center, 1100 9th Avenue, Seattle, WA 98111, USA
    Surg Oncol Clin N Am 13:663-74, ix. 2004
    ....
  3. ncbi request reprint Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma
    V J Picozzi
    Section of Hematology Oncology, Virginia Mason Medical Center, Seattle, Washington 98111, USA
    Oncology (Williston Park) 15:1296-306; discussion 1310-1, 1314. 2001
    ..02). This assessment of chemotherapy delivery to patients with intermediate-grade NHL showed significant variation from current standards. Further analysis of factors influencing chemotherapy delivery might improve therapeutic outcomes...
  4. ncbi request reprint Strength of the evidence: adjuvant therapy for resected pancreatic cancer
    Vincent J Picozzi
    Section of Medical Oncology, Virginia Mason Medical Center, 1100 Ninth Ave Buck 2, Seattle, WA 98111, USA
    J Gastrointest Surg 12:657-61. 2008
    ..Additional randomized trials are needed to address significant areas of controversy within available data...
  5. pmc Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031
    V J Picozzi
    Department of Medical Oncology, Virginia Mason Medical Center, Seattle, WA 98111, USA
    Ann Oncol 22:348-54. 2011
    ..The American College of Surgeons Oncology Group sought to confirm the efficacy of a novel interferon-based chemoradiation regimen in a multicenter phase II trial...
  6. doi request reprint Afferent limb syndrome and delayed GI problems after pancreaticoduodenectomy for pancreatic cancer: single-center, 14-year experience
    Rahul Pannala
    Department of Gastroenterology and Hepatology, Virginia Mason Medical Center, Seattle, Washington, USA
    Gastrointest Endosc 74:295-302. 2011
    ..There are limited data on the incidence of afferent limb syndrome and other delayed GI problems in pancreatic cancer (PaC) patients, especially among long-term survivors (>2 years)...
  7. doi request reprint Supportive care considerations during concurrent chemoradiotherapy for pancreatic adenocarcinoma: lessons learned from clinical experience
    Andrea Wang-Gillam
    Division of Hematology Oncology, Siteman Cancer Center, Washington University in St Louis School of Medicine, St Louis, MO Department of Radiation Oncology, Rush University Medical Center Department of Surgery, University of Chicago Medical Center, Chicago, IL Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX Cancer and Digestive Diseases Institutes, Virginia Mason Medical Center, Seattle, WA
    Am J Clin Oncol 36:637-43. 2013
    ..Planning for the treatment of side effects before the anticancer therapy begins facilitates therapy administration and improves patient tolerance. ..
  8. ncbi request reprint Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma
    Andrew D Jacobs
    Section of Hematology Oncology, Virginia Mason Medical Center, Seattle, Washington 98111, USA
    Cancer Invest 22:505-14. 2004
    ..To assess the efficacy and toxicity of combination therapy with gemcitabine and docetaxel in patients with unresectable pancreatic carcinoma...